KNIGHT CAPITOL CONSULTANTS for SANOFI US SERVICES INC (FORMERLY KNOWN AS "SANOFI-AVENTIS U S INC )
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Disaster Planning/Emergencies DIS
General issues related to reauthorization of the Pandemic and All Hazards Preparedness Act (no legislation yet)
Foreign entity interest: anofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so, too, Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | (previously listed) |
Taxation/Internal Revenue Code TAX
Extension of Research and Development Tax Credit (P.L. 111-142), Tax Extenders Legislation (P.L. 111-312) and such provisions included in "The American Research and Competitiveness Act of 2011" (H.R. 942).
Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so, too, Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Previously Listed |
Copyright/Patent/Trademark CPT
Provisions related to the pharmaceutical industry in the Leahy-Smith America Invents Act (P.L. 112-29) Legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 27 and deliberations of Deficit Reduction Committee).
Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so, too, Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Professional Staff, House Approps Cmte |
Health Issues HCR
Monitor issues of interest to the pharmaceutical industry with respect to implementation of, possible changes in, or repeal of all or parts of the Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152), including the Independent Payment Advisory Board, coverage of pharmaceuticals under Medicare Parts B and D; and awareness and issues related to access to diabetes care and also atrial fibrillation care, including H.Res. 295, S. Res. 243.
Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so, too, Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | previously listed |
Torts TOR
Possible changes to the Vaccine Injury Compensation Program (no legislation yet)
Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so, too, Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | (Previously listed) |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| SANOFI SA | France | France | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.